LGP signs ~$2M supply agreement with Ilios Santé

Highlights:

• LGP signs two-year ~$2 million medicinal cannabis supply agreement with Ilios Santé in Germany
• Ilios Santé to purchase minimum annual quantities of a high-THC white-label medicinal cannabis flower product being developed by LGP
• Ilios Santé is a licensed pharmaceutical wholesaler headquartered in Frankfurt and wholly-owned subsidiary of The Bloomwell Group, a leading European medical cannabis healthcare company
• The Agreement represents continued validation of LGP’s key strategy of developing bespoke, high-value white label strains for export to lucrative jurisdictions, and further consolidates LGP’s growing industry reputation as one of the leading global pure-play medicinal cannabis suppliers operating in Europe

Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) is pleased to announce its entry into an agreement with Frankfurt-headquartered and licenced pharmaceutical wholesaler, Ilios Santé GmbH (“Ilios Santé”) for the supply of a non-exclusive LGP white label medicinal cannabis product into Germany (“Agreement”).

The Agreement highlights the continued success of LGP’s extensive genetics program which has resulted in a
world-class bank of cannabis cultivars including over 20 strains in various stages of development. The Agreement is a welcome addition to LGP’s rapidly expanding suite of high-value supply agreements from its
Danish Facility into the EU, joining agreements with AMP, Demecan and Four 20 Pharma in Germany (see ASX
announcements dated 19 January, 19 April and 19 May 2022 respectively) with an aggregate potential value of ~$35 million over three years. These agreements represent the fruition of LGP’s strategy of producing large volume bespoke strain white-label products for supply into Europe and the UK while servicing these markets with its own, LGP branded products. The Agreement also consolidates LGP’s growing industry reputation as one of the leading global pure-play medicinal cannabis suppliers operating in Europe

For more on this announcement please see the LGP Investor Centre

By Little Green Pharma